EDIT - Editas' gene editing therapy for sickle cell disease gets FDA's regenerative medicine status
2023-10-16 09:44:49 ET
More on Editas Medicine
- Editas Medicine: A Mispriced Contender In The Gene Editing Arena
- Editas Medicine: RUBY Gems, Sparkling Catalysts In Sickle Cell Arena
- Editas gains as Stifel upgrades on sickle cell disease potential
For further details see:
Editas' gene editing therapy for sickle cell disease gets FDA's regenerative medicine status